Displaying drugs 3401 - 3425 of 11612 in total
Mavacamten
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved...
Approved
Investigational
Matched Description: … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart …
Lubiprostone
Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. Activation of these channels promotes the secretion of a chloride-rich fluid that soften...
Approved
Investigational
Matched Description: … A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels ... Lubiprostone is a medication used in the management of idiopathic chronic constipation. ... Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase …
Fraxinus velutina pollen
Fraxinus velutina pollen is the pollen of the Fraxinus velutina plant. Fraxinus velutina pollen is mainly used in allergenic testing.
Approved
Coral snake (micrurus fulvius) immune globulin antivenin (equine)
North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. It is intravenously administered so that the antivenin binds to and neutralizes coral snake venom.
The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins...
Approved
Experimental
Matched Description: … North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment ... The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by …
Vigabatrin
Vigabatrin is an analog of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only the...
Approved
Matched Description: … Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. ... have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a …
Desflurane
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane.[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888]
Desflurane was granted...
Approved
Matched Description: … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than ... It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled …
Interferon beta-1b
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Approved
Iodine povacrylex
Iodine povacrylex (DuraPrep) is a surgical solution, film-forming iodophor complex that provides fast acting, persistent, broad-spectrum antimicrobial activity. DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria
that can potentially cause skin infection....
Approved
Matched Description: … It is a broad spectrum antiseptic and can provide almost 99.9% antiseptic conditions. ... Iodine povacrylex (DuraPrep) is a surgical solution, film-forming iodophor complex that provides fast ... DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation …
Ciclesonide
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Approved
Investigational
Matched Description: … Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. …
Eslicarbazepine acetate
Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body....
Approved
Matched Description: … Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active …
Chenopodium album pollen
Chenopodium album pollen is the pollen of the Chenopodium album plant. Chenopodium album pollen is mainly used in allergenic testing.
Approved
Artemisia frigida pollen
Artemisia frigida pollen is the pollen of the Artemisia frigida plant. Artemisia frigida pollen is mainly used in allergenic testing.
Approved
Triticum aestivum pollen
Triticum aestivum pollen is the pollen of the Triticum aestivum plant. Triticum aestivum pollen is mainly used in allergenic testing.
Approved
Tocilizumab
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a...
Approved
Matched Description: … Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory ... [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385] ... [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and …
Dihydroergotamine
A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.
Recent improvements have been made in the design of intranasal delivery devices allowing...
Approved
Investigational
Matched Description: … A 9,10alpha-dihydro derivative of [ergotamine]. …
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Indium In-111 chloride
Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for in vivo diagnostic imaging procedures and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures. It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in...
Approved
Matched Description: … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint ... It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI. …
Fostamatinib
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA .
Recently,...
Approved
Investigational
Matched Description: … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory …
Lorlatinib
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Matched Description: … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic ... ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a …
Enflurane
Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.[L13646,L13649] Unlike its other inhalational anesthetic counterparts including isoflurane and halothane, enflurane is known to induce seizure activity. In addition, it is known to cause increased cardio...
Approved
Investigational
Vet approved
Matched Description: … Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. …
Sulfanilamide
Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
Approved
Matched Description: … Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline. …
Ivabradine
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus...
Approved
Matched Description: … Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis ... Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for ... dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium …
Eflapegrastim
Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … [L43135]
Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled ... to the Fc fragment of human IgG4 via a polyethylene glycol linker. ... co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a …
Talquetamab
Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. Talquetamab binds to GPRC5D, a cell surface...
Approved
Investigational
Matched Description: … Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed ... arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a ... [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma …
Ciltacabtagene autoleucel
Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000, and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience a range of symptoms including...
Approved
Investigational
Matched Description: … [L40739] Patient T-cells are reprogrammed with a transgene encoding a specific chimeric antigen receptor ... Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. ... [L40749] There have been a number of treatments developed for multiple myeloma (e.g. …
Displaying drugs 3401 - 3425 of 11612 in total